No approved therapies yet target YAP/TAZ directly, though research is intense, such as YAP inhibitors to halt tumor growth or approaches to transiently activate YAP for regenerative purposes.[100] The challenge is that Hippo signaling is highly context‐dependent, and upstream triggers are not fully elucidated,[100] making it hard to intervene without broad effects. Here, YAP1 is linked to neoplasm.